FAQ on Lantern Pharma Inc.'s Completion of Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial

What is the Phase 2 HARMONIC(TM) trial about?

The Phase 2 HARMONIC(TM) trial evaluates the investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients, particularly those who have relapsed after tyrosine kinase inhibitor therapy, alongside standard chemotherapy agents.

Why is Japan a strategic region for this trial?

Japan has a high incidence of never-smoker NSCLC cases, making it a strategic region for the trial to address an under-addressed patient group with limited treatment options.

How many patients were enrolled in Japan for the trial?

Lantern Pharma enrolled 10 patients across five sites in Japan, including the National Cancer Center in Tokyo.

What makes Lantern Pharma’s approach unique in this trial?

Lantern Pharma utilizes an AI-driven approach to identify and accelerate the development of therapies for underserved cancer markets, potentially offering more targeted and effective treatment options.

When is additional trial data expected?

Additional trial data from Taiwan and the U.S. is expected later in Q3 2025.

Who is involved in the Phase 2 HARMONIC(TM) trial?

The trial involves never-smoker NSCLC patients, particularly those who have relapsed after tyrosine kinase inhibitor therapy, and is conducted by Lantern Pharma Inc. across selected sites in Japan, Taiwan, and the U.S.

What are the implications of completing enrollment ahead of schedule?

Completing enrollment ahead of schedule underscores Lantern Pharma’s efficiency and commitment to addressing the needs of never-smoker NSCLC patients, potentially accelerating the development of LP-300 as a treatment option.

Where can I find more information about Lantern Pharma Inc. and its trials?

More information is available in the company’s newsroom at https://ibn.fm/LTRN and through specialized communications platforms like BioMedWire.